In palliative care, the relief of the dyspnea is necessary. Medications for the reduction of dyspnea have side effects. High-flow nasal cannula oxygen therapy (HFNC) is a new way to deliver oxygen. Investigators hypothesize that HNFC is an acceptable technic for the patient with dyspnea in palliative care.

A pilot study with 30 patients will be conducted. Acceptability of HNFC will be studied by the time of use by patients of the HNFC during one week. The effectiveness of HNFC in relieving dyspnea will be studied using Borg scale.

Pilot study for acceptability of high flow nasal cannula oxygen therapy in palliative care Population: 30 patients in palliative care (for lung cancer, terminal respiratory failure) who suffer from dyspnea and have oxygen therapy. Patients with curative care are excluded and patients who require non invasive ventilation.

An oral consent is asked.

Primary objective: acceptability of HNFC in patients with dyspnea in palliative care during one week

Secondary objectives:

• Tolerance of HNFC at short term (1h and 24h) and long term (7 days) after initiation of HNFC
• Efficiency of HNFC at short term

Primary outcome: duration of use of the HNFC during 7 days

Secondary outcome:

• Tolerance: noise of the system of HNFC, side effects of high flow (nasal dryness..)
• Efficiency: evaluation of dyspnea by Borg scale and measure of respiratory rate and saturation of oxygen one hour after initiation of HNFC

Inclusion Criteria:

• Patient followed for respiratory failure with palliative care and :
• More than 18 years old
• Dyspnea related to a respiratory disease
• Hypoxemia requiring the introduction of more than 4 liters of oxygen for a sp02 > 90%
• Patient affiliated to a social security system

Exclusion Criteria:

• Patient less than 18 years old
• Patient with guardianship, trusteeship
• No consent for participation at the study
• Project of curative care